Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™
Retrieved on:
Wednesday, January 18, 2023
FDA, Other Health, Health, Cannabis, Pharmaceutical, Oncology, Other Science, Infectious Diseases, Surgery, Science, Clinical Trials, International Association, Analgesic, CNS, CRADA, Trauma, Walter Reed Army Institute of Research, American Pain Society, Department of Defense Serum Repository, IASP, Conference, Journal of Surgical Research, Central nervous system, Investigational New Drug, Post-traumatic stress disorder, Interest group, IND, Daubert v. Merrell Dow Pharmaceuticals, Inc., Pain management, APS, Physician, Pharmaceutical industry, Anesthesiology
Probudur’s proprietary formulation is intended for immediate onset and has demonstrated sustained pain control for up to 96 hours in animal studies.
Key Points:
- Probudur’s proprietary formulation is intended for immediate onset and has demonstrated sustained pain control for up to 96 hours in animal studies.
- Dr. Neil Singla is board certified in Anesthesiology and the Founder and Chief Scientific Officer of Lotus Clinical Research, a leading analgesic clinical research organization (CRO) with extensive analgesic and pain-related expertise.
- Dr. Singla has published extensively and is a frequent lecturer for physicians, pharmaceutical companies, and medical research institutes throughout the country.
- “Virpax is actively moving its programs forward in anticipation of filing Investigational New Drug applications (INDs) and beginning human clinical trials.